Floatz logo

Red Blood Cells

Head Injury

ThermoFisher Scientific Brahms Biomarkers FranceCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Head Injury cohort.

Asset / SponsorPhaseRating
Aspirin
Hadassah Medical Organization
Phase 4BB
Oxygen
Jay C. Buckey Jr.
Phase 4BB
Sodium Lactate
Institut d'Anesthesiologie des Alpes Maritimes
Phase 2/3B
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Pierre-Julien CUNGI
Phase 2CCC
Sufentanyl
Pierre-Julien CUNGI
Phase 2CCC
Rosuvastatin
Universidad Autonoma de San Luis Potosí
Phase 1/2CCC
Nepenthe
Dalhousie University
Phase 1/2CCC
Mannitol
Massachusetts General Hospital
Phase 1/2CCC

Same molecule, other indications

Red Blood Cells is also rated in:

beta-thalassemia majorDormant
B
Indicative · Phase 3
62 / 100
View asset →
relapsing-remitting multiple sclerosisActive
CC
Indicative · Phase 1
46 / 100
View asset →
bronchopulmonary dysplasiaActive
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →